Understanding Immunotherapy: Molecular and Cellular Perspectives

Understanding Immunotherapy: Molecular and Cellular Perspectives

• January 15, 2016
• Reading time: 2 minutes

Immunotherapy can be broadly categorized into two main branches: molecular immunotherapy and cellular immunotherapy.

Molecular immunotherapy includes small-molecule drugs and monoclonal antibodies derived from biological sources. These agents are designed to induce an immune response or block specific signaling pathways in cancer cells, thereby inhibiting their spread and facilitating their destruction by the immune system.

Cellular immunotherapy involves harvesting a patient's own immune cells from their blood. These cells are then genetically engineered or expanded in a laboratory to enhance their ability to recognize and eradicate cancer cells more effectively. Once re-infused into the patient, these "supercharged" immune cells target the malignancy with significantly fewer side effects compared to traditional chemotherapy, such as severe nausea and vomiting, thereby improving the patient's quality of life.

In Taiwan, two molecular immunotherapies have been approved, primarily for the treatment of malignant melanoma. While several other molecular immunotherapies for cancers such as colorectal, head and neck, liver, and lung cancer are available internationally, access in Taiwan often requires complex special import applications. Streamlining these regulatory processes is essential for improving patient access to life-saving medications.

While cellular immunotherapy is often viewed as a breakthrough for patients with advanced-stage cancer, many of these treatments remain in the clinical trial phase. It is important to recognize that many novel therapies, including various cell-based and vaccine-based treatments, carry inherent risks until they have successfully passed rigorous clinical validation. Patients are strongly advised to seek guidance from ethical medical professionals and oncology specialists to ensure treatment quality and patient safety.

Currently, there is high demand for information regarding cellular immunotherapy, with many patients traveling abroad to access these treatments. While the regulatory landscape for molecular immunotherapy in Taiwan is evolving, the primary challenge remains the administrative complexity of the application process.

Source: Adapted from Yahoo Editorial.

Related to Immunotherapy

• Discovering the Key to Aggressive Pancreatic Cancer!
• New Immune Enhancers Boosting Cancer Immunotherapy
• Kyoto University Launches iPS Cell Cancer Therapy!

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4